Clinical and cytogenetic characteristics and KIT mutation status according to CBFB-MYH11 fusion type in 208 patients with de novo AML and inv(16)/t(16;16)
| Characteristic . | Non–type A fusion* (n = 26) . | Type A fusion (n = 182) . | P . |
|---|---|---|---|
| Age, y | .75 | ||
| Median | 41 | 41 | |
| Range | 22-62 | 17-74 | |
| Sex, no. of males (%) | 14 (54) | 113 (62) | .52 |
| Race, no. (%) | .56 | ||
| White | 20 (77) | 149 (82) | |
| Nonwhite | 6 (23) | 33 (18) | |
| Hemoglobin, g/dL | .42 | ||
| Median | 8.9 | 8.8 | |
| Range | 6.6-13.0 | 3.1-14.8 | |
| Platelet count, × 109/L | .33 | ||
| Median | 46 | 42 | |
| Range | 15-208 | 7-272 | |
| WBC, × 109/L | .007 | ||
| Median | 21.9 | 33.8 | |
| Range | 1.4-87.2 | 0.4-500.0 | |
| Percentage of blood blasts | .26 | ||
| Median | 43 | 52 | |
| Range | 3-93 | 0-97 | |
| Percentage of BM blasts | .59 | ||
| Median | 53 | 58 | |
| Range | 22-93 | 2-89 | |
| FAB (centrally reviewed), no. (%) | .04 | ||
| M1 | 3 (14) | 2 (1) | |
| M2 | 0 (0) | 8 (5) | |
| M4 | 4 (19) | 21 (14) | |
| M4Eo | 14 (67) | 121 (78) | |
| M5 | 0 (0) | 3 (2) | |
| Cytogenetic characteristics‡ | |||
| sole inv(16)/t(16;16), no. (%) | 10 (42) | 114 (63) | .07 |
| +8, no. (%) | 7 (29) | 18 (10) | .01 |
| +13, no. (%) | 2 (8) | 3 (2) | .11 |
| +21, no. (%) | 6 (25) | 1 (1) | < .001 |
| +22, no. (%) | 0 (0) | 35 (19) | .02 |
| KIT, no. (%)§ | .002 | ||
| Mutated | 0 (0) | 48 (27) | |
| Wild-type | 24 (100) | 130 (73) |
| Characteristic . | Non–type A fusion* (n = 26) . | Type A fusion (n = 182) . | P . |
|---|---|---|---|
| Age, y | .75 | ||
| Median | 41 | 41 | |
| Range | 22-62 | 17-74 | |
| Sex, no. of males (%) | 14 (54) | 113 (62) | .52 |
| Race, no. (%) | .56 | ||
| White | 20 (77) | 149 (82) | |
| Nonwhite | 6 (23) | 33 (18) | |
| Hemoglobin, g/dL | .42 | ||
| Median | 8.9 | 8.8 | |
| Range | 6.6-13.0 | 3.1-14.8 | |
| Platelet count, × 109/L | .33 | ||
| Median | 46 | 42 | |
| Range | 15-208 | 7-272 | |
| WBC, × 109/L | .007 | ||
| Median | 21.9 | 33.8 | |
| Range | 1.4-87.2 | 0.4-500.0 | |
| Percentage of blood blasts | .26 | ||
| Median | 43 | 52 | |
| Range | 3-93 | 0-97 | |
| Percentage of BM blasts | .59 | ||
| Median | 53 | 58 | |
| Range | 22-93 | 2-89 | |
| FAB (centrally reviewed), no. (%) | .04 | ||
| M1 | 3 (14) | 2 (1) | |
| M2 | 0 (0) | 8 (5) | |
| M4 | 4 (19) | 21 (14) | |
| M4Eo | 14 (67) | 121 (78) | |
| M5 | 0 (0) | 3 (2) | |
| Cytogenetic characteristics‡ | |||
| sole inv(16)/t(16;16), no. (%) | 10 (42) | 114 (63) | .07 |
| +8, no. (%) | 7 (29) | 18 (10) | .01 |
| +13, no. (%) | 2 (8) | 3 (2) | .11 |
| +21, no. (%) | 6 (25) | 1 (1) | < .001 |
| +22, no. (%) | 0 (0) | 35 (19) | .02 |
| KIT, no. (%)§ | .002 | ||
| Mutated | 0 (0) | 48 (27) | |
| Wild-type | 24 (100) | 130 (73) |
FAB indicates French-American-British classification; and WBC, white blood count.
Type E (n = 18), type D (n = 6), type I (n = 2).
Patients may have multiple secondary abnormalities and thus can be classified in more than 1 category; 3 patient samples had no mitoses.
Six patients (2 with non–type A and 4 with type A fusions) had no material available to study KIT mutations and thus have an unknown KIT mutation status.